{
    "organizations": [],
    "uuid": "2416f7340446f8c77e3f8e3c4df17a0da71d692c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-verastem-submits-marketing-applica/brief-verastem-submits-marketing-application-to-fda-for-duvelisib-idUSASB0C4FI",
    "ord_in_thread": 0,
    "title": "BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 7, 2018 / 12:14 PM / in 25 minutes BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Verastem Inc: \n* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA \n* VERASTEM INC - LOOK FORWARD TO WORKING WITH FDA DURING REVIEW PROCESS AND TO POTENTIAL U.S. APPROVAL DECISION FOR DUVELISIB IN EARLY 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T14:14:00.000+02:00",
    "crawled": "2018-02-07T14:43:21.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "submits",
        "marketing",
        "application",
        "fda",
        "duvelisib",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "verastem",
        "inc",
        "verastem",
        "submits",
        "new",
        "drug",
        "application",
        "fda",
        "duvelisib",
        "treatment",
        "patient",
        "relapsed",
        "refractory",
        "chronic",
        "lymphocytic",
        "lymphocytic",
        "lymphoma",
        "follicular",
        "lymphoma",
        "verastem",
        "inc",
        "look",
        "forward",
        "working",
        "fda",
        "review",
        "process",
        "potential",
        "approval",
        "decision",
        "duvelisib",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}